Envestnet Asset Management Inc. Increases Holdings in Envista Holdings Corporation $NVST

Envestnet Asset Management Inc. raised its holdings in shares of Envista Holdings Corporation (NYSE:NVST) by 15.0% in the 2nd quarter, HoldingsChannel reports. The fund owned 230,759 shares of the company’s stock after buying an additional 30,051 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Envista were worth $4,509,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Parallel Advisors LLC lifted its stake in Envista by 100.1% during the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after purchasing an additional 1,397 shares during the last quarter. FourThought Financial Partners LLC acquired a new stake in Envista during the first quarter worth approximately $180,000. Vestcor Inc purchased a new stake in shares of Envista during the 1st quarter worth approximately $211,000. Aigen Investment Management LP acquired a new position in shares of Envista in the 1st quarter valued at $274,000. Finally, State of Wyoming boosted its holdings in shares of Envista by 121.1% in the 1st quarter. State of Wyoming now owns 16,911 shares of the company’s stock valued at $292,000 after buying an additional 9,264 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NVST shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a research note on Tuesday. Piper Sandler lifted their target price on Envista from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Wells Fargo & Company upped their target price on Envista from $17.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. UBS Group raised their price target on Envista from $18.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 29th. Finally, Robert W. Baird set a $27.00 price objective on Envista in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $21.33.

Envista Stock Performance

Shares of NVST stock opened at $19.87 on Friday. The stock’s 50-day moving average price is $20.34 and its 200 day moving average price is $19.65. The company has a quick ratio of 2.08, a current ratio of 2.44 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $3.27 billion, a PE ratio of 62.11, a price-to-earnings-growth ratio of 1.09 and a beta of 1.05. Envista Holdings Corporation has a 52-week low of $14.22 and a 52-week high of $22.68.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Envista had a return on equity of 4.84% and a net margin of 2.11%.The company had revenue of $669.90 million for the quarter, compared to the consensus estimate of $639.49 million. During the same period last year, the business posted $0.12 EPS. The company’s revenue was up 11.5% on a year-over-year basis. As a group, equities research analysts forecast that Envista Holdings Corporation will post 1 EPS for the current year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.